Study raises doubts about rapid Covid tests’ reliability; how telehealth companies are cutting costs

A new study raises significant doubts about whether the tests can detect the Omicron variant before infected people can transmit the virus to others. ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

Sponsored by        Study raises doubts about rapid Covid tests' reliability in early days after infection By Matthew Herper Joe Raedle/Getty Images The study included the Abbott BinaxNow and Quidel Quickvue rapid antigen tests, both of which are authorized by the FDA. Read More STAT+: Chatbots, surveys, and texts: Telehealth companies cut costs by reimagining the front desk By Mohana Ravindranath Adobe Telehealth companies are automating more of their services as they look to provide care for more patients at a lower cost. Read More STAT+: 3 CRISPR editing innovations to watch in 2022 By Megan Molteni Hyacinth Empinado/STAT Here are three emerging CRISPR editing technologies that we think it’s worth keeping an eye on in 2022 and beyond. Read More Sponsor content by Dana-Farber Cancer Institute Study reveals groups at high risk for multiple myeloma have elevated rates of a precursor condition People over 50 who are Black or have a close relative with a blood cancer were found in the PROMISE study to have a rate of 13 percent of monoclonal gammopathy of unknown significance (MGUS), which can progress to multiple myeloma. Investigators say screening of high-risk groups to detect individuals with MGUS could, when combined with regular monitoring and treatment, improve the survival of patients who develop myeloma. Read more. Robert Califf is a fervent believer in data. At the FDA, will that be enough? By Matthew Herper Manuel Balce Ceneta/AP He avoids black-and-white thinking and values nuance. But those tendencies might not always serve him well in Washington. Read More STAT+: The health tech tracker for the first quarter: 13 decisive industry events and deals to watch By Mohana Ravindranath and Katie Palmer and Mario Aguilar PATRICK T. FALLON/AFP via Getty Images Here are the events, deals, and lobbying blitzes that will shape how the health tech industry fares in the first quarter of 2022. Read More Predicting preeclampsia from a blood test holds promise for pregnancy complications By Elizabeth Cooney Adobe Marked by hypertension, preeclampsia usually surfaces late in pregnancy, posing an immediate risk of preterm birth, stillbirth, and death. Read More Opinion: 'Protect our hospitals' might convince Britons to get Covid-19 vaccines, but it won't work in the U.S. By Gregory D. Stevens JOSEPH PREZIOSO/AFP via Getty Images "Protect the NHS" has been an effective vaccination call to action in the U.K. "Protect our hospitals" won't work well in the U.S. Read More Opinion: The case for Califf: Don't let politics prevent confirmation of best FDA commissioner candidate By Jeffrey A. Lieberman Andrew Harnik/AP Three senators' "concerns" about Robert Califf show a disturbing lack of understanding of the experience needed to lead the FDA. Read More Wednesday, January 5, 2022       1 Exchange Pl, Suite 201, Boston, MA 02109 ©2022, All Rights Reserved. I no longer wish to receive STAT emails Update Email Preferences | Contact Us | View In Browser